PHOTO
- Middle East pharma companies investing resources as oncology becomes one of the highest-selling and fastest-growing therapy areas in the region
- Increased life expectancy, lifestyle, eating habits and obesity all factors contributing to the demand for cancer drugs and medicines
Abu Dhabi, United Arab Emirates, 28th July: CPhI Middle East & Africa, the leading global pharmaceutical event, will address the growing demand for innovative medicines and drugs to treat cancer patients, during the opening day panel discussions, when the event returns to the Abu Dhabi National Exhibition Centre (ADNEC) from 16-18 September.
Key features of the Spotlight on Oncology and the Future Trends session will include the latest developments in screening and treatment across the Middle East region, the balancing act between cost pressures and innovation, and the experiences from the global market.
According to statistics from medical research and consultancy firm IQVIA, health authorities and private practices across the Middle East spend US$556 million annually on cancer treatment, the market is currently being driven by the growth in the cost of targeted therapies which account for 73% of total Middle East sales.
Cara Turner, Brand Director – Pharma, UBM EMEA, the organisers of the event, said: “In recent years, we have seen several launches of targeted cancer treatments take place in the Middle East region. Health authority recognition of the benefits these new drugs offer has helped underscore the innovation-rewarding nature of the region, both from a targeted oncology therapy perspective, but also from a wider pharmaceutical standpoint.”
Despite the increase of new drugs and targeted therapy launches for cancer treatments, there are still several gaps in cancer care in the Middle East. Issues include a time lag between FDA approval and launch in Middle East markets, with Lebanon, UAE and KSA taking up to 1.5 years, 1.8 years and 2.4 years respectively.
Other factors include a lack of cancer awareness, which has led to health professionals underestimating the scale of the problem, a lack of advanced diagnostics centres, late-stage diagnosis, and limited access to appropriate treatment. This is in addition to several issues relating to continuity of care due to affordability – an issue which is prominent in Egypt, Lebanon and with GCC expats – as well as patient support infrastructure and inconsistent treatment.
On a global scale, spending on cancer treatments is expected to reach US$200 billion by 2022, with the number of medicines in clinical development increasing the opportunities for continued advancement. Looking ahead, advances in technology and the use of information will have a direct impact on treatment and costs over the next decade.
At CPhI Middle East & Africa, oncology will be discussed by industry experts including Dr. Sawsan Al Madhi, Director General of Friends of Cancer Patients; Tamer Ali, Commercial Head Saudi Arabia and Oncology Practice Lead, IQVIA; Manel Chikh, CEO Zaphyr Pharmaceuticals; and Khaled Fahim, Medical Manager, Merck Middle East.
“During the discussion, key topics such as oncology pricing, purchasing, patient support programs, treatment management and the effectiveness of cancer apps to support patients will all be debated to determine the best practices for the region’s cancer treatment market,” said Turner.
In addition to oncology on day one, CPhI Middle East & Africa, which recently signed a Memorandum of Understanding (MOU) with the Ministry of Health and Prevention (MoHaP) and will see the government agency sponsor and partner with the conference, will focus on a further two days of discussion targeting the most important issues impacting the Middle East & Africa pharmaceutical market.
Over 294 local, regional and international exhibitors from more than 35 countries are expected to attend the three-day showcase. In addition to the global network of exhibitors, the event is expected to attract over 4,900 participants, more than 50 per cent of which will come from the Middle East & Africa region.
For registration or further information, please visit www.cphi.com/mea.
ENDS
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, North America, Korea, China, India, Japan, Southeast Asia and the Middle East, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.
For more information visit: www.cphi.com
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.
Media contact
JAMES LAKIE
General Manager
Tel: +971 4 365 2711 | Mobile: +971 50 153 6544
E-mail: james.lakie@shamalcomms.com
Office 106, Arjaan Office Tower, Dubai Media City
PO Box 502701 | Dubai, United Arab Emirates
Website: www.shamalcomms.com
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
